BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:23:58 2024-05-20 am EDT			5-day change	1st Jan Change
0.59 ^EUR	+3.15%		0.00%	-45.37%

May. 15	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI
May. 02	Benevolentai S.A. Announces Directorate Changes	CI

BenevolentAI société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022

March 16, 2023 at 06:30 am EDT

BenevolentAI société anonyme reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was GBP 10.56 million compared to GBP 4.63 million a year ago. Net loss was GBP 163.93 million compared to GBP 107.66 million a year ago.

Latest news about BenevolentAI

BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	May. 15	CI
Benevolentai S.A. Announces Directorate Changes	May. 02	CI
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	Apr. 15	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
Kenneth Mulvany Sends a Letter to Benovelent AI	Apr. 02	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	Mar. 25	CI
BenevolentAI Announces Executive Changes	Mar. 20	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member	Jan. 24	CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer	Jan. 24	CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO	Jan. 22	AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	23-09-26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
BenevolentAI S.A. Announces Executive Changes	23-09-21	CI
BenevolentAI S.A. Announces Management Changes	23-09-21	CI
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery	23-09-20	DJ
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	23-09-20	MT
BenevolentAI Signs Strategic Collaboration with Merck	23-09-20	CI
BenevolentAI Appoints Chief Revenue Officer	23-09-18	MT
BenevolentAI Appoints Catherine Isted as Chief Financial Officer	23-09-11	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	23-08-31	CI
BenevolentAI Announces Retirement of Jackie Hunter as Non-Executive Director	23-06-21	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	23-06-05	CI

Chart BenevolentAI

Duration

Period

More charts

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Sector

Biotechnology & Medical Research

Calendar

2024-09-23 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5044 GBP

Average target price

1.632 GBP

Spread / Average Target

+223.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-45.37%	75.83M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research